Company profile: Avidity Biosciences
1.1 - Company Overview
Company description
- Provider of oligonucleotide-based therapies leveraging an Antibody Oligonucleotide Conjugates (AOCs) platform that combines monoclonal antibodies with oligonucleotides to target genetic drivers of disease. Pipeline includes AOC 1001 for DM1 (Phase 3) to reduce DMPK mRNA, AOC 1020 for FSHD (Phase 1/2) to reduce DUX4 mRNA/protein, and AOC 1044 for DMD exon 44 skipping (Phase 1/2).
Products and services
- Antibody Oligonucleotide Conjugates (AOCs) Platform: Monoclonal antibody-based, this technology combines monoclonal antibodies with oligonucleotide therapies to target genetic drivers of diseases
- AOC 1001 (Del-desiran): Clinical-stage, engineered therapy entering Phase 3 for DM1, designed to reduce levels of DMPK mRNA
- AOC 1020: Targeted treatment in Phase 1/2 for FSHD, aimed at reducing DUX4 mRNA and protein expression
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Avidity Biosciences
Prevail Therapeutics
HQ: United States
Website
- Description: Provider of novel AAV9-based gene therapies for neurodegenerative diseases. Offerings include PR001, delivering a healthy GBA1 gene to correct lysosomal dysfunction in Parkinson's disease with GBA1 mutations and Type 1 Gaucher disease, and PR006, delivering a healthy GRN gene to raise progranulin for frontotemporal dementia.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Prevail Therapeutics company profile →
Voyager Therapeutics
HQ: United States
Website
- Description: Provider of gene therapy and neurology-focused biotechnology solutions, offering the TRACER AAV capsid discovery platform for BBB-crossing capsids and a pipeline including anti-tau antibody (VY-TAU01), SOD1 silencing gene therapy (VY9323) for ALS, tau and anti-Aβ gene therapies for Alzheimer’s, and FXN gene therapy for Friedreich’s Ataxia.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Voyager Therapeutics company profile →
American Gene Technologies
HQ: United States
Website
- Description: Provider of gene therapy solutions for infectious diseases, cancers, and inherited disorders. Offerings include AGT103-T, an autologous genetically modified cell product to repair HIV-related immune damage and enable natural control of replication; a PKU gene therapy expected to enter trials in 2025; an immuno-oncology program activating γδ T cells to destroy solid tumors; and a proprietary gene-delivery platform.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full American Gene Technologies company profile →
RetroSense Therapeutics
HQ: United States
Website
- Description: Provider of gene therapies for vision restoration, developing treatments to restore sight in patients with blindness due to retinitis pigmentosa (RP) and advanced dry age-related macular degeneration (advanced dry-AMD), conditions for which there are currently no FDA-approved drugs to improve or restore vision.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full RetroSense Therapeutics company profile →
Oncotelic Therapeutics
HQ: United States
Website
- Description: Provider of immuno-oncology therapeutics, developing RNA therapeutics and small molecule drugs against cancer and infectious diseases.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Oncotelic Therapeutics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Avidity Biosciences
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Avidity Biosciences
2.2 - Growth funds investing in similar companies to Avidity Biosciences
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Avidity Biosciences
4.2 - Public trading comparable groups for Avidity Biosciences
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →